focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good AfterNoon
There are alot of things Going On Behind the scenes in my view
But i would like you guys To Know that Vectura has a great product in its Hands
thats these Smart Inhalers Products
they also have numerous JV partners
we have a sittuation that is THESE SMART INHALERS will be used in a big way to deliver Drugs Directly to the Lungs weather it might be a Vaccine or A TREATMENT like REMESDIVIR of Gilead sciences some people call it the wonder Drug
Vectura are in the best position to reep the rewards
the pharma companys will be queing up to do JOINT VENTURES with the Vectura
dont let it miss your RADAR we ARE going to 180 pence
You can be sure the serious Pharma Companies want to partner with Vectura
What has this to do with Vectura!
Well it looks like it did not quite make it, it should be on the reserve list though and it is quite likely that there will be several moving from this into the index over the next quarter.
I always wonder to what extent the price changes in some of the companies on the borders at the rebalance are the result of alignment for the rebalance or a degree of manipulation to ensure the elevation (or otherwise) of a particular company.
It does seem odd that with a share buyback started that the price is the lowest it has been since early May.....
The Board maintains its financial guidance and outlook expectations for 2020.
As separately announced today, the Group has entered into arrangements with Numis Securities Limited to execute the second £10 million tranche of its previously announced £20 million share buyback programme. The buyback is expected to commence on 1 June 2020.
Deliver strong financial performance in 2020
– VR315 (US) and QVM149 approval
– Reducing our R&D costs
– Deliver partnered portfolio and new CDMO business
• Company transformation well underway
– New leadership appointments to drive operational excellence and customer
service focus
– Diversifying customer base and building opportunity funnel
– Investing in innovation, technology and product development
Second £10m tranche of buyback to start, FTSE 250 beckons and a nice solid trading update.
RNS - steady as she goes.
https://vectura.podbean.com/
Great Podcast for Vectura Followers
Vectura Group PLC (LON:VEC) has drawn attention to a recommendation relating to the use of one of the company’s asthma treatment formulations in Europe.
In a statement, the company noted that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Novartis's Enerzair Breezhaler (QVM149).
Enerzair Breezhaler, which uses a formulation devised and licensed by Vectura, is a maintenance treatment for uncontrolled asthma in adult patients. Uncontrolled patients are those whose asthma is not adequately controlled with a maintenance combination of a long-acting beta2 agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year.
A final decision from the European Commission regarding the grant of a marketing authorisation is expected to be received roughly two months after a CHMP opinion. Upon European regulatory approval, Vectura will be eligible to receive a US$5.0 million milestone and thereafter a low-single-digit royalty on net sales.
As you say Mr BB several 'trees' in play with vec. The court case, drug trails and next ftse rebalance.
I think that as things stand this rise will put them into the ftse250 at the June rebalance, if not they will certainly easily make the reserve list. The indexes are so fluid at the moment it is hard to keep track though.
Early days so best not to get too excited about what be 2 consecutive positive days but may be more to do with the US appeal court giving GSK additional time to submit their final paper arguments, which we apparently agreed to ,although I am sot sure which we would agree to GSK having more time to prepare their defense -which could substantial millions of $$$.Unless, of course, we have effectively settled & the settlement may soon be announced , ends the uncertainty & results in millions of $$$s being deposited in our bank account sooner rather than later .
Others here may understand the legal protocols involved in such cases in the US & I may well be barking up the wrong tree -although there are several trees in play currently
Monks, good point about the inhaler . We have now achieved the small uplift I was expecting ref rns.
However I still remain hopeful of significant inhaler sales uplift and sp rise as a result.
With the share buyback through the big market dip it has held up quite well. I think that there has also been some buying and selling around its possible entry into the 250. As you say this news should help it up a bit. I have wondered if it would get a lift from possible applications in treating covid - the initial interferon trails, which look positive, used an inhaler (but did not specify which).
Decent rns today and more cash will roll in. Should uplift sp by a few %.
Have the inhalers breathed new life into the sp?
Good news yesterday -new senior appointment ,a former colleague of our CEO & he is beginning to impose his plans & philosophy on Vec ,with which ,as along suffering shareholder (ex SKP) ,I wish him every success
Corona virus -The recommendation for people with asthma is to carry their flutiform inhaler with them. Clearly the demand for these will rise significantly as people become anxious about the spread. More might also be prescribed. Good news for vec imv.
Looking forward to the release of VR315US this year.
They supply Vectura so hopefully the SP will reflect this soon.
Berenburg may well be onto something.
Fluti production is flat out at Recipharm formerly Sanofi, 4 shifts in manufacture and filling and 4 shifts in packing 24/7. Happy days!!!!
VEC’s results said it should conclude by Q1 2021
How long do appeals take - depends on the lawyers - they will drag it out as long as possible to maximise their fees , oh and if they win it is a bonus but not the priority obviously , imv.
How long do these appeals take?
Why are we up today , anyone any ideas?
Today is the day GSK start their appeal. Fingers crossed the judge chucks it’s out sooner rather than later “Appellants Glaxo Group Limited and GlaxoSmithKline LLC. The opening brief is due 01/24/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding.“